Management of schizophrenia

Source: Wikipedia, the free encyclopedia.
Management of schizophrenia
SpecialtyPsychiatry

The management of schizophrenia usually involves many aspects including psychological, pharmacological, social, educational, and employment-related interventions directed to recovery, and reducing the impact of schizophrenia on quality of life, social functioning, and longevity.[1]

Hospitalization

Hospitalization may occur with severe episodes of

Assertive Community Treatment team, supported employment[3]
and patient-led support groups. Efforts to avoid repeated hospitalization include the obtaining of community treatment orders which, following judicial approval, coerce the affected individual to receive psychiatric treatment including long-acting injections of anti-psychotic medication. This legal mechanism has been shown to increase the affected patient's time out of the hospital.[4]

Medication

Risperidone (trade name Risperdal) is a common atypical antipsychotic medication.

The mainstay of treatment for schizophrenia is an

Janssen-Cilag, and should be interpreted with this in mind.[9] In those on antipsychotics, continued use decreases the risk of relapse.[10][11] There is little evidence regarding consistent benefits from their use beyond two or three years.[11]

Treatment of schizophrenia changed dramatically in the mid-1950s with the development and introduction of the first antipsychotic chlorpromazine.[12] Others such as haloperidol and trifluoperazine soon followed.

It remains unclear whether the newer antipsychotics reduce the chances of developing neuroleptic malignant syndrome, a rare but serious and potentially fatal neurological disorder most often caused by an adverse reaction to antipsychotics (neuroleptics).[13]

Most people on antipsychotics get side effects. People on typical antipsychotics tend to have a higher rate of

extrapyramidal side effects while some atypicals are associated with considerable weight gain, diabetes, and risk of metabolic syndrome; this is most pronounced with olanzapine, while risperidone and quetiapine are also associated with weight gain.[9] Risperidone has a similar rate of extrapyramidal symptoms to haloperidol.[9] The American Psychiatric Association generally recommends that atypicals be used as first line treatment in most patients, but further states that therapy should be individually optimized for each patient.[14]

The response of symptoms to medication is variable; treatment resistant schizophrenia is the failure to respond to two or more antipsychotic medications given in therapeutic doses for six weeks or more.[15] Patients in this category may be prescribed clozapine, a medication that may be more effective at reducing symptoms of schizophrenia, but treatment may come with a higher risk of several potentially lethal side effects including agranulocytosis and myocarditis.[16][17] Clozapine is the only medication proven to be more effective for people who do not respond to other types of antipsychotics.[18] It also appears to reduce suicide in people with schizophrenia. As clozapine suppresses the development of bone marrow, in turn reducing white blood cells which can lead to infection, blood tests are taken for the first six months on this medication.[19] The risk of experiencing agranulocytosis due to clozapine treatment is higher in elderly people, children, and adolescents.[16] The effectiveness in the studies also needs to be interpreted with caution as the studies may have an increased risk of bias.[16]

Studies have found that antipsychotic treatment following NMS and neutropenia may sometimes be successfully rechallenged (restarted) with clozapine.[20][21]

Tobacco smoking increases the metabolism of some antipsychotics, by strongly activitating CYP1A2, the enzyme that breaks them down, and a significant difference is found in these levels between smokers and non-smokers.[22][23][24] It is recommended that the dosage for those smokers on clozapine be increased by 50%, and for those on olanzapine by 30%.[23] The result of stopping smoking can lead to an increased concentration of the antipsychotic that may result in toxicity, so that monitoring of effects would need to take place with a view to decreasing the dosage; many symptoms may be noticeably worsened, and extreme fatigue, and seizures are also possible with a risk of relapse. Likewise those who resume smoking may need their dosages adjusted accordingly.[22][25] The altering effects are due to compounds in tobacco smoke and not to nicotine; the use of nicotine replacement therapy therefore has the equivalent effect of stopping smoking and monitoring would still be needed.[22]

Research findings suggested that other neurotransmission systems, including serotonin, glutamate, GABA, and acetylcholine, were implicated in the development of schizophrenia, and that a more inclusive medication was needed.

FDA in December 2019 for the treatment of schizophrenia in adults.[24][26][27] Lumateperone is a small molecule agent that shows improved safety, and tolerance. It interacts with dopamine, serotonin, and glutamate in a complex, uniquely selective manner, and is seen to improve negative and positive symptoms, and social functioning.[28] Lumateperone was also found to reduce potential metabolic dysfunction, have lower rates of movement disorders, and have lower cardiovascular side effects such as a fast heart rate.[24]

Add-on agents

Sometimes the use of a second antipsychotic in combination with another is recommended where there has been a poor response. A review of this use found some evidence for an improvement in symptoms but not for relapse or hospitalisation. The use of combination antipsychotics is increasing in spite of limited supporting evidence, with some countries including Finland, France, and the UK recommending its use and others including Canada, Denmark, and Spain in opposition.

repetitive transcranial magnetic stimulation
(rTMS) but evidence for these is lacking.

Note: Only adjuncts for which at least one double-blind randomized placebo-controlled trial has provided support are listed in this table.

Adjuncts[30][31] Symptoms against which efficacy is known Notable adverse effects seen in clinical trials Highest quality of clinical data available N Notes
Adjuncts to clozapine[32][33]
Antipsychotics
Amisulpride Global Extrapyramidal side effects (e.g. tremor, dystonia, akathisia, etc.), headache, somnolence, insomnia, elevated serum prolactin, etc. 1 DB-RPCTs 16 Not approved for use in the
US or Canada. Approved for use in Australia, Europe and several countries in East Asia. Can prolong the QT interval, some in vivo evidence[34]
suggests it may have anti-diabetogenic effects and hence may improve metabolic parameters in patients on clozapine.
Aripiprazole Global, esp. negative Akathisia 1 DB-RPCT 61 Can also improve metabolic side effects of clozapine (including body weight). Six studies so far; only one negative.
Risperidone Global Impaired cognitive functioning, prolactin elevation and hyperglycaemia 2 DB-RPCTs, 1 DB-RCT 357 (DB-RPCTs) & 24 (DB-RCT) 11 studies have been conducted, 5 negative. A meta-analysis[32] found no clinically significant difference between risperidone augmentation and placebo augmentation.
Sulpiride Global Increased serum prolactin 1 DB-RPCT 28 Not approved for use in the US, Canada and Australia.
Ziprasidone Global
QTc interval
prolongation		 1 DB-RCT 24 Was compared with risperidone in the one DB-RCT.
Antidepressants
Citalopram Negative symptoms Well tolerated 1 DB-RPCT 61 Can prolong the QT interval and since clozapine can prolong the QT interval too it is advisable to avoid their concurrent use in patients with cardiovascular risk factors.
Fluvoxamine Negative and depressive symptoms Elevated serum levels of clozapine (via inhibition of P450 cytochromes) Open-label studies NA Improved metabolic parameters
Mirtazapine Negative, depressive and cognitive symptoms Weight gain 2 DB-RPCTs (1 negative) 80 5-HT2A/2C/3 & α2 adrenoceptor antagonist
Anticonvulsants
Lamotrigine Negative & depressive symptoms Stevens–Johnson syndrome, toxic epidermal necrolysis, etc. 4 DB-RPCTs (2 negative) 108 Usually a relatively well tolerated anticonvulsant, but because of risk of potentially-fatal dermatologic AEs the dose must be slowly titrated up in order to prevent these AEs. A meta-analysis[32] found that it was ineffective.
Topiramate Negative symptoms Cognitive impairment, sedation, asthenia 2 DB-RPCTs (1 negative) 57 Can cause cognitive impairment and hence should probably be avoided in patients with cognitive impairments.
Valproate Reduced anxiety & depression Weight gain, hair loss One open-label study comparing it with lithium NA Increases the expression of
GAD67 via histone deacetylase
(HDAC) inhibition.
Glutamatergic agents[35][36]
CX-516 Global Well tolerated 1 DB-RPCT 18 Statistically significant improvement in total symptoms but no significant improvement in negative and positive symptoms when considered separately.
Memantine Global Well tolerated 1 DB-RPCT 21 Statistically significant improvement in negative and total symptomtology.
Other
Lithium Global Weight gain, hypersalivation 1 DB-RPCT, 1 DB-RCT 10 (DB-RPCT), 20 (DB-RCT) Increased risk of neurological side effects such as neuroleptic malignant syndrome.
E-EPA Global (especially negative and cognitive symptoms) Well tolerated 3 DB-RPCT (1 negative) 131 Ester of the omega-3 fatty acid, eicosapentaenoic acid.
Adjuncts to other antipsychotics
Anti-inflammatory agents[37][38]
Aspirin[39][40] Global (especially positive symptoms) Well tolerated 1 DB-RPCT 70 Increased risk of bleeding, but seems relatively well tolerated.
Celecoxib Global (especially negative symptoms) Well tolerated 3 DB-RPCTs (1 negative) 147 May increased the risk of cardiovascular events (which is particularly worrisome as schizophrenia patients are a higher risk group for cardiovascular events). Case series (N=2) suggests efficacy in augmenting clozapine.
Minocycline[41][42][43][44] Global Well tolerated 4 DB-RPCTs 164 Increased risk of blood dyscarsias.
Omega-3 fatty acids
 Global Well tolerated 6 DB-RPCTs (1 negative)[45] 362 May have protective effects against depression.
Pregnenolone[46][47][48][49] Global Well tolerated 3 DB-RPCTs 100 Levels of this neurosteroid in the body are elevated by clozapine treatment.
Glutamatergics[35][50]
D-alanine[51][52]
 Global Well tolerated 1 DB-RPCT 31 A D-amino acid with affinity towards the glycine site on the NMDA receptor.
D-serine
 Global (especially negative symptoms) Well tolerated 4 DB-RPCTs 183 Affinity towards the glycine site on NMDA receptors. D. Souza 2013,[53] Heresco-Levy 2005,[54] Lane 2005,[55] Lane 2010,[56] Tsai 1999,[57] Weiser 2012[58]
Glycine Global (predominantly positive symptoms) Well tolerated 5 DB-RPCTs 219 Endogenous NMDA receptor ligand.
N-acetylcysteine[59] Global (especially negative symptoms) Well tolerated 3 DB-RPCTs 140 Cystine and glutathione prodrug.[60][61] Cystine increases intracellular glutamate levels via the glutamate-cystine anti porter.

Berk 2008,[62] Berk 2011,[63] Carmeli 2012,[64] Lavoie 2008[65]

Sarcosine Global (especially negative symptoms) Well tolerated 3 DB-RPCTs 112
GlyT1 antagonist (i.e. glycine reuptake inhibitor). Also known as N-methylglycine. Lane 2005,[55] Lane 2006,[66] Lane 2008,[67] Lane 2010,[56] Tsai 2004[68]
Cholinergics[69][36][70]
Donepezil Global Well tolerated 6 DB-RPCTs (5 negative; or 12 DB-RPCTs if one includes cross-over trials; 8 negative in total) 378, 474 (including cross-over trials) Possesses antidepressant effects according to one trial.
Galantamine Cognition Well tolerated 5 DB-RPCTs (1 negative) 170 Robust nootropic
Rivastigmine Cognition Well tolerated 3 DB-RPCTs (all 3 negative; 5 trials including cross-over trials; 4 negative) 93, 131 (including cross-over trials) Seems to be a weaker nootropic
Tropisetron†[71][72][73][74] Cognitive and negative symptoms Well tolerated 3 DB-RPCTs 120 Agonist at
α7 nAChRs; antagonist at 5-HT3
. Expensive (>$20 AUD/tablet).
Antidepressants[75]
Escitalopram†[76] Negative symptoms Well tolerated 1 DB-RPCT 40 May increase risk of QT interval prolongation.
Fluoxetine Negative symptoms Well tolerated 4 DB-RPCTs (3 negative) 136 The safest of antidepressants listed here in overdose.[77] Risk of QT interval prolongation is lower than with escitalopram (but still exists).
Mianserin[78] Negative and cognitive symptoms Well tolerated 2 DB-RPCTs 48 Weight gain, sedation, dry mouth, constipation and dizziness. Blood dyscarsias are a possible adverse effect and both the Australian Medicines Handbook and British National Formulary 65 (BNF 65) recommend regular complete blood counts to be taken.[79][80]
Mirtazapine[78] Cognition,[81][82] negative and positive symptoms†[83] Well tolerated ≥4 DB-RPCTs (one negative) 127 Relatively safe in overdose. Produces significant sedation and weight gain, however, which could potentially add to the adverse effects of atypical antipsychotics. Can reduce antipsychotic-induced akathisia.[84]
Ritanserin Negative symptoms Well tolerated 2 DB-RPCTs 73 5-HT2A/2C antagonist. Not clinically available.
Trazodone Negative symptoms Well tolerated 2 DB-RPCTs 72 5-HT2A antagonist and SSRI. Has sedative effects and hence might exacerbate some of the side effects of atypical antipsychotics.
Other
Alpha-lipoic acid[85][86]
 Weight gain Well tolerated 1 DB-RPCT 360 Offset antipsychotic drug-induced weight gain. Increased total antioxidant status. May also increase GSH:GSSG (reduced glutathione:oxidized glutathione) ratio.[87]
L-Theanine[88][89][90]
 Positive, activation, and anxiety symptoms Well tolerated 2 DB-RPCTs 40 Glutamic acid analog. Primary study noted reduction in positive, activation, and anxiety symptoms. Additional studies have noted improvements in attention.[91][92][93][94] Research suggests that theanime has a regulatory effect on the nicotine acetylcholine receptor-dopamine reward pathway, and was shown to reduced dopamine production in the midbrain of mice.[95]
Famotidine†[96] Global Well tolerated 1 DB-RPCT 30 May reduce the absorption of vitamin B12 from the stomach. Might also increase susceptibility to food poisoning.
Ginkgo biloba Tardive dyskinesia, positive symptoms Well tolerated 4 DB-RPCTs 157 Atmaca 2005,[97] Doruk 2008,[98] Zhang 2001,[99] Zhang 2001,[100] Zhang 2006,[101] Zhang 2011,[102] Zhou 1999[103]
Ondansetron[104] Negative and cognitive symptoms Well tolerated 3 DB-RPCTs 151 5-HT3 antagonist. May prolong the QT interval. Expensive (>$4 AUD/tablet).
SAM-e[105]
 Aggression Well tolerated 1 DB-RPCT 18 Study noted improvement of aggressive behavior and quality of life impairment. while in another study SAM-e has been purported to have a contributory effect on psychosis [106]
Vitamin C[107][108][109][110] Global Well tolerated 1 DB-RPCT 40 Improves
BPRS
scores.

Acronyms used:
DB-RPCT — Double-blind randomized placebo-controlled trial.
DB-RCT — Double-blind randomized controlled trial.

Note: Global in the context of schizophrenia symptoms here refers to all four symptom clusters.

N refers to the total sample sizes (including placebo groups) of DB-RCTs.

† No secondary sources could be found on the utility of the drug in question, treating the symptom in question (or any symptom in the case of where † has been placed next to the drug's name).

Psychosocial

Psychotherapy is also widely recommended, though not widely used in the treatment of schizophrenia, due to reimbursement problems or lack of training. As a result, treatment is often confined to psychiatric medication.[111]

Cognitive behavioral therapy (CBT) is used to target specific symptoms and improve related issues such as self-esteem and social functioning. Although the results of early trials were inconclusive[112] as the therapy advanced from its initial applications in the mid-1990s, meta-analytic reviews suggested CBT to be an effective treatment for the psychotic symptoms of schizophrenia.[113][114] Nonetheless, more recent meta analyses have cast doubt upon the utility of CBT as a treatment for the symptoms of psychosis.[115][116][117]

Another approach is

fMRI.[118]

Metacognitive training (MCT): In view of many empirical findings [119] suggesting deficits of metacognition (thinking about one's thinking, reflecting upon one's cognitive process) in patients with schizophrenia, metacognitive training (MCT) [119][120] is increasingly adopted as a complementary treatment approach. MCT aims at sharpening the awareness of patients for a variety of cognitive biases (e.g. jumping to conclusions, attributional biases, over-confidence in errors), which are implicated in the formation and maintenance of schizophrenia positive symptoms (especially delusions),[121] and to ultimately replace these biases with functional cognitive strategies. The training consists of 8 modules and can be obtained cost-free from the internet in 15 languages.[119][120] Studies confirm the training's feasibility [122] and efficacy in ameliorating positive psychosis symptoms.[123][124] Studies of single training module show that this intervention target specific cognitive biases.[125] Recently, an individualized format has been developed which combines the metacognitive approach with methods derived from cognitive-behavioral therapy.[126]

Family Therapy or Education, which addresses the whole family system of an individual with a diagnosis of schizophrenia, may be beneficial, at least if the duration of intervention is longer-term.[127][128][129] A 2010 Cochrane review concluded that many of the clinical trials that studied the effectiveness of family interventions were poorly designed, and may over estimate the effectiveness of the therapy. High-quality randomized controlled trials in this area are required.[129] Aside from therapy, the impact of schizophrenia on families and the burden on careers has been recognized, with the increasing availability of self-help books on the subject.[130][131] There is also some evidence for benefits from social skills training, although there have also been significant negative findings.[132][14] Some studies have explored the possible benefits of music therapy and other creative therapies.[133][134][135]

The Soteria model is alternative to inpatient hospitalization using full non professional care and a minimal medication approach.[136] Although evidence is limited, a review found the program equally as effective as treatment with medications but due to the limited evidence did not recommend it as a standard treatment.[137] Training in the detection of subtle facial expressions has been used to improve facial emotional recognition.[138]

Avatar Therapy, developed by Professor Julian Leff, was developed to help patients deal with the impact of auditory hallucinations. A 2020 Cochrane review however failed to find any consistent effects in the reviewed studies.[139]

Supplements

Disruption of the gut microbiota has been linked to inflammation, and disorders of the central nervous system. This includes schizophrenia, and probiotic supplementation has been proposed to improve its symptoms. A review found no evidence to support this but it concludes that probiotics may be of benefit in regulating bowel movements and lessening the metabolic effects of antipsychotics.[140]

A review explains the need for an optimal level of vitamin D and omega-3 fatty acids for the proper synthesis and control of the neurotransmitter serotonin. Serotonin regulates executive function, sensory gating, and social behavior – all of which are commonly impaired in schizophrenia. The model proposed suggests that supplementation would help in preventing and treating these brain dysfunctions.[141] Another review finds that omega-3 fatty acids and vitamin D are among the nutritional factors known to have a beneficial effect on mental health.[142] A Cochrane review found evidence to suggest that the use of omega-3 fatty acids in the prodromal stage may prevent the transition to psychosis but the evidence was poor quality and further studies were called for.[143]

Treatment resistant schizophrenia

About half of those with schizophrenia will respond favourably to antipsychotics, and have a good return of functioning.[144] However, positive symptoms persist in up to a third of people. Following two trials of different antipsychotics over six weeks, that also prove ineffective, they will be classed as having treatment resistant schizophrenia (TRS), and clozapine will be offered.[145][146] Clozapine is of benefit to around half of this group although it has the potentially serious side effect of agranulocytosis (lowered white blood cell count) in less than 4% of people.[147][148][149] Between 12 and 20 per cent will not respond to clozapine and this group is said to have ultra treatment resistant schizophrenia.[145][150] ECT may be offered to treat TRS as an add-on therapy, and is shown to sometimes be of benefit.[150] A review concluded that this use only has an effect on medium-term TRS and that there is not enough evidence to support its use other than for this group.[151]

TRS is often accompanied by a low quality of life, and greater social dysfunction.[152] TRS may be the result of inadequate rather than inefficient treatment; it also may be a false label due to medication not being taken regularly, or at all.[153] About 16 per cent of people who had initially been responsive to treatment later develop resistance. This could relate to the length of time on APs, with treatment becoming less responsive.[154] This finding also supports the involvement of dopamine in the development of schizophrenia.[153] Studies suggest that TRS may be a more heritable form.[155]

TRS may be evident from first episode psychosis, or from a relapse. It can vary in its intensity and response to other therapies.[152] This variation is seen to possibly indicate an underlying neurobiology such as dopamine supersensitivity (DSS), glutamate or serotonin dysfunction, inflammation and oxidative stress.[145] Studies have found that dopamine supersensitivity is found in up to 70% of those with TRS.[156] The variation has led to the suggestion that treatment responsive and treatment resistant schizophrenia be considered as two different subtypes.[145][155] It is further suggested that if the subtypes could be distinguished at an early stage significant implications could follow for treatment considerations, and for research.[150] Neuroimaging studies have found a significant decrease in the volume of grey matter in those with TRS with no such change seen in those who are treatment responsive.[150] In those with ultra treatment resistance the decrease in grey matter volume was larger.[145][150]

Rehabilitative interventions

Individual Placement and Support (IPS), where the rehabilitated person is directly placed and supported in the workplace with the support of a professional, promotes the employment of people with schizophrenia and their survival in the open labour market better than the model of gradual work practice before placement.[157]

Research evidence on the relative superiority of different types of housing units for people with psychosis in terms of symptomatic or functional development is scarce. The support and independence provided in a residential unit should be flexible, individualised and, as far as possible, at the choice of the person being rehabilitated. The living environment should be as normal as possible and the rehabilitated person should not be isolated from the rest of the community.[158][159]

Traditional Chinese medicine

Acupuncture is a procedure generally known to be safe and with few adverse effects. A Cochrane review found limited evidence for its possible antipsychotic effects in the treatment of schizophrenia and called for more studies.[160] Another review found limited evidence for its use as an add-on therapy for the relief of symptoms but positive results were found for the treatment of sleep disorders that often accompany schizophrenia.[161]

Wendan decoction is a classic herbal treatment in traditional Chinese medicine used for symptoms of psychosis, and other conditions. Wendan decoction is safe, accessible, and inexpensive, and a Cochrane review was carried out for its possible effects on schizophrenia symptoms. Limited evidence was found for its positive antipsychotic effects in the short term, and it was associated with fewer adverse effects. Used as an add-on to an antipsychotic, wider positive effects were found. Larger studies of improved quality were called for.[162][163]

Other

Various brain stimulation techniques have been used to treat the positive symptoms of schizophrenia, in particular

repetitive transcranial magnetic stimulation (rTMS).[165] Transcranial magnetic stimulation is low-cost, noninvasive, and almost free of side-effects making it a good therapeutic choice with promising outcomes.[164] Low-frequency TMS of the left temporoparietal cortex (the region containing Broca's area) can reduce auditory hallucinations.[164] rTMS seems to be the most effective treatment for those with persistent AVHs, as an add-on therapy.[165] AVHs are not resolved in up to 30 per cent of those on antipsychotics and a further percentage still experience only a partial response.[165] Techniques based on focused ultrasound for deep brain stimulation could provide insight for the treatment of AVHs.[165]

An established brain stimulation treatment is

NICE guidelines in the UK for catatonia if previously effective, though there is no recommendation for use for schizophrenia otherwise.[167] Psychosurgery has now become a rare procedure and is not a recommended treatment for schizophrenia.[168]

A study in 2014 conducted by an Australian researcher indicated that the

mitochondrial activity over a period of 180 days under a sustained intake of 1000 mg/day.[169]

There may be some benefit in trying several treatment modalities at the same time, especially those that could be classed as lifestyle interventions.[170] Nidotherapy is suggested to be a cost-effective social prescribing intervention using efforts to change the environment to improve functional ability.[171]

Numerous people diagnosed with schizophrenia have found it necessary to organize confidential groups with each other where they can discuss their experiences without clinicians present.[172][173] Peer support in which people with experiential knowledge of mental illness provide knowledge, experience, emotional, social or practical help to each other is considered an important aspect of coping with schizophrenia and other serious mental health conditions. A 2019 Cochrane reviews of evidence for peer-support interventions compared to supportive or psychosocial interventions were unable to support or refute the effectiveness of peer-support due to limited data.[174]

References

  1. ^ "Psychosis and schizophrenia in adults: treatment and management | Key-priorities-for-implementation | Guidance and guidelines". The United Kingdom National Institute for Health and Care Excellence (NICE). 12 February 2014.
  2. S2CID 34615961
    .
  3. PMID 17329468
    .
  4. PMID 16020822
    .
  5. ISBN 978-1-901242-97-3. Archived from the original
    on 2007-09-27.
  6. PMID 25854979
    .
  7. PMID 20704164
    .
  8. S2CID 14598183
    .
  9. ^
    PMID 23870705. Archived from the original
    on 2014-09-11.
  10. S2CID 2018124
    .
  11. ^
    PMID 23512950
    .
  12. S2CID 33739419
    .
  13. S2CID 32752143
    .
  14. ^ a b Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, et al. (February 2004). "Practice Guideline for the Treatment of Patients With Schizophrenia". American Journal of Psychiatry. 161 (2 supplement) (2nd ed.). American Psychological Association (APA). Archived from the original on 2014-03-06.
  15. ISBN 978-0-19-251496-7
    .
  16. ^
    PMID 19160174
    .
  17. S2CID 1153693
    .
  18. S2CID 22499842
    .
  19. ISBN 978-0-13-197653-5
    .
  20. S2CID 3689529
    .
  21. S2CID 189945135
    .
  22. ^
    PMID 28550660
    .
  23. ^
    PMID 24595134
    .
  24. ^
    PMID 27291902
    .
  25. S2CID 11456024
    .
  26. ^ "FDA Approves Caplyta (lumateperone) for the Treatment of Schizophrenia in Adults". drugs.com. 23 December 2019.
  27. S2CID 211110160
    .
  28. PMID 33012872
    .
  29. PMID 28658515
    .
  30. S2CID 7705779
    .
  31. S2CID 2077519
    .
  32. ^
    S2CID 39716777
    .
  33. PMID 21422107
    .
  34. S2CID 28553141
    .
  35. ^
    S2CID 207299820
    .
  36. ^
    PMID 23999481
    .
  37. PMID 23151612
    .
  38. PMID 24106335
    .
  39. PMID 20492850
    .
  40. PMID 31425623
    .
  41. S2CID 5908680
    .
  42. S2CID 5442977
    .
  43. S2CID 19246435
    .
  44. S2CID 10554795
    .
  45. PMID 16855961
    .
  46. S2CID 25628072
    .
  47. PMID 19339966
    .
  48. PMID 23240026
    .
  49. S2CID 2499760
    .
  50. PMID 22987851
    .
  51. S2CID 10174006
    .
  52. S2CID 19372446
    .
  53. PMID 23093223
    .
  54. S2CID 46348188
    .
  55. ^
    PMID 16275807
    .
  56. ^
    PMID 19887019
    .
  57. S2CID 29054148
    .
  58. PMID 22795211
    .
  59. PMID 21118657
    .
  60. PMID 19008644
    .
  61. PMID 2000395
    .
  62. S2CID 10321144
    .
  63. PMID 20868637
    .
  64. PMID 22383949
    .
  65. S2CID 237232
    .
  66. S2CID 42741531
    .
  67. S2CID 26037874
    .
  68. S2CID 35723786
    .
  69. PMID 22258978
    .
  70. S2CID 45807136
    .
  71. S2CID 25260365
    .
  72. PMID 20573264
    .
  73. PMID 22952075
    .
  74. S2CID 15652697
    .
  75. PMID 20807960
    .
  76. S2CID 261170
    .
  77. PMID 19031375
    .
  78. ^
    S2CID 36119981
    .
  79. ISBN 978-0-9805790-9-3
    .
  80. ISBN 978-0-85711-084-8
    .
  81. S2CID 7705779
    .
  82. PMID 23491969
    .
  83. S2CID 37328991
    .
  84. S2CID 31506138
    .
  85. PMID 21187189
    .
  86. S2CID 7873991
    .
  87. PMID 18315507
    .
  88. S2CID 4937207
    .
  89. S2CID 9786949
    .
  90. S2CID 206849271
    .
  91. PMID 18641209
    .
  92. S2CID 19296401
    .
  93. S2CID 13232338
    .
  94. PMID 18296328
    .
  95. S2CID 17803427
    .
  96. S2CID 13048121
    .
  97. S2CID 1892988
    .
  98. S2CID 42478246
    .
  99. S2CID 7836683
    .
  100. PMID 11775047
    .
  101. S2CID 12411168
    .
  102. S2CID 37085462
    .
  103. PMID 11721446
    .
  104. S2CID 21574153
    .
  105. S2CID 207712279
    .
  106. S2CID 25378736
    .
  107. S2CID 24917071
    .
  108. PMID 23885048
    .
  109. PMID 20688474
    .
  110. PMID 20454891
    .
  111. doi:10.1176/pn.40.22.0024b
    .
  112. PMID 15495000
    . (Retracted)
  113. PMID 17962231
    .
  114. S2CID 31560136
    .
  115. S2CID 1001891
    .
  116. ^ Newton‐Howes, Giles and Rebecca Wood. "Cognitive behavioural therapy and the psychopathology of schizophrenia: Systematic review and meta‐analysis." Psychology and Psychotherapy: Theory, Research and Practice (2011).
  117. PMID 21491377
    .
  118. S2CID 221295938
    .
  119. ^
    S2CID 3193086
    .
  120. ^ a b Moritz S, Woodward TS, Burlon M (2005). "Metacognitive skill training for patients with schizophrenia (MCT)" (PDF). Hamburg: VanHam Campus. Retrieved 1 April 2011. {{cite journal}}: Cite journal requires |journal= (help)
  121. S2CID 24541273
    .
  122. ^ Moritz S, Woodward TS (2007). "Metacognitive training for schizophrenia patients (MCT): A pilot study on feasibility, treatment adherence, and subjective efficacy" (PDF). German Journal of Psychiatry. 10: 69–78. Archived from the original (PDF) on 2016-03-05. Retrieved 2011-04-01.
  123. PMID 27847929
    .
  124. PMID 26748396
    .
  125. S2CID 151353395
    .
  126. ^ Moritz S, Veckenstedt R, Randjbar S, Vitzthum F (in press). "Individualized metacognitive therapy for people with schizophrenia psychosis (MCT+)", Springer, Heidelberg. [clarification needed]
  127. PMID 12728780
    .
  128. S2CID 25863992
    .
  129. ^
    PMID 21154340
    .
  130. ISBN 978-1-85168-344-4
    .
  131. ISBN 978-0-06-084259-8
    .
  132. PMID 16885207
    .
  133. PMID 17077429
    .
  134. PMID 16235338
    .
  135. PMID 17253555
    .
  136. PMID 10086470
    .
  137. PMID 17573357
    .
  138. ISBN 9789400708341
    .
  139. PMID 32413166
    .
  140. PMID 30947230
    .
  141. S2CID 2368912
    .
  142. PMID 27482518
    .
  143. PMID 31689359
    .
  144. PMID 27216902
    .
  145. ^
    PMID 28086761
    .
  146. PMID 28655284
    .
  147. S2CID 208792724. Archived from the original
    (PDF) on 23 June 2013. Retrieved 23 December 2011.
  148. PMID 17626963
    .
  149. PMID 19160174
    .
  150. ^
    PMID 31911624
    .
  151. PMID 30888709
    .
  152. ^
    PMID 25070124
    .
  153. ^
    S2CID 207492339
    .
  154. S2CID 6929780
    .
  155. ^
    PMID 30170114
    .
  156. S2CID 147704473
    .
  157. ^ "Skitsofreniapotilaiden tuettu työllistyminen". www.kaypahoito.fi. Retrieved 2023-04-03.
  158. S2CID 32054475
    .
  159. PMID 29764420
    .
  160. PMID 25330045
    .
  161. PMID 29601477
    .
  162. PMID 28657646
    .
  163. PMID 29062436
    .
  164. ^
    PMID 28350371
    .
  165. ^
    PMID 31413576
    .
  166. PMID 15774232
    .
  167. ^ National Institute for Health and Clinical Excellence (April 2003). "The clinical effectiveness and cost effectiveness of electroconvulsive Therapy (ECT) for depressive illness, schizophrenia, catatonia and mania". National Institute for Health and Clinical Excellence. Retrieved 2007-06-17.
  168. S2CID 10303872
    .
  169. ^ Laupu WK (2014). The efficacy of Garcinia mangostana L. (mangosteen) pericarp as an adjunctive to second-generation antipsychotics for the treatment of schizophrenia: a double blind, randomised, placebo-controlled trial (phd). James Cook University. 40097. Retrieved April 24, 2017.
  170. S2CID 151705012
    .
  171. PMID 31059613
    .
  172. PMID 21510914
    .
  173. PMID 24936088
    .
  174. PMID 30946482
    .
Retrieved from "https://en.wikipedia.org/w/index.php?title=Management_of_schizophrenia&oldid=1215908092"